The potential effect of iopamidol contrast on renal function in patients infected with SARS-CoV-2 virus: A...

Many types of computed tomography (CT) scans require the use of contrast. Acute kidney injury (AKI) is a known adverse effect of intravenous contrast administration. To our knowledge, the effects of low-osmolar contrast agents such as iopamidol on renal function in patients infected with the SARS-CoV-2 virus have never been studied. This study investigates the incidence of AKI following iopamidol contrast administration in patients infected with the SARS-CoV-2 virus.

This retrospective cohort study included two groups: patients who received CT pulmonary angiography who were infected with SARS-CoV-2 virus and those who tested negative for SARS-CoV-2. Data were collected from the electronic medical record of a single hospital from January 1, 2020, to September 15, 2020. AKI was defined using the Kidney Disease: Improving Global Outcomes definition: increase in serum creatinine by ≥0.3 mg/dL (≥26.5 mcmol/L) within 48 h, or increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or urine volume <0.5 mL/kg/h for 6 h.

AKI occurred in 13.51% of patients in the SARS-CoV-2 positive group and 16.92% of patients in the negative group. Using a two-sample test to compare the equality of proportions (with continuity correction factor), we found there is no significant difference in the two proportions (P = 0.3735).

There was no significant difference in the incidence of AKI between SARS-CoV-2 positive and negative groups. Given the limitations of this study, further work must be done on this topic.